Therapeutic Antibodies in HIV Treatment - Classical Approaches to Novel Advances

Abela, Irene A.; Reynell, Lucy; Trkola, Alexandra
November 2010
Current Pharmaceutical Design;11/28/2010, Vol. 16 Issue 33, p3754
Academic Journal
No abstract available.


Related Articles

  • Functional Characterization of Two scFv-Fc Antibodies from an HIV Controller Selected on Soluble HIV-1 Env Complexes: A Neutralizing V3- and a Trimer-Specific gp41 Antibody. Trott, Maria; Wei╬▓, Svenja; Antoni, Sascha; Koch, Joachim; von Briesen, Hagen; Hust, Michael; Dietrich, Ursula // PLoS ONE;May2014, Vol. 9 Issue 5, p1 

    HIV neutralizing antibodies (nAbs) represent an important tool in view of prophylactic and therapeutic applications for HIV-1 infection. Patients chronically infected by HIV-1 represent a valuable source for nAbs. HIV controllers, including long-term non-progressors (LTNP) and elite controllers...

  • Blockade of the CD154-CD40 costimulatory pathway prevents the development of experimental autoimmune glomerulonephritis. Reynolds, John; Khan, Sarah B.; Allen, Andrew R.; Benjamin, Christopher D.; Pusey, Charles D. // Kidney International;Oct2004, Vol. 66 Issue 4, p1444 

    Blockade of the CD154-CD40 costimulatory pathway prevents the development of experimental autoimmune glomerulonephritis.Background.Experimental autoimmune glomerulonephritis (EAG) was induced in Wistar-Kyoto (WKY) rats by immunization with rat glomerular basement membrane (GBM) in adjuvant. This...

  • Research may lead to new therapeutics against HIV-1.  // Infectious Disease News;Apr2014, Vol. 27 Issue 4, p22 

    The article discusses a study led by Sara Crespillo, first published online on December 3, 2013 in "The Journal of Biological Chemistry," on anti-HIV monoclonal antibodies' roles in binding affinity and implications for the development of new HIV treatments or vaccines.

  • Biological therapies directed against cells in autoimmune disease. Hasler, Paul // Springer Seminars in Immunopathology;Jun2006, Vol. 27 Issue 4, p443 

    Among the cells of the immune system involved in the pathogenesis of autoimmune disease, T cells have received the most attention. The central role of these cells in several animal models of autoimmune diseases and in human disease counterparts has provided the rationale for specific therapeutic...

  • Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1. Kong, Yi-chi M.; Flynn, Jeffrey C. // Frontiers in Immunology;May2014, Vol. 5, p1 

    To improve the efficacy of immunotherapy for cancer and autoimmune diseases, recent ongoing and completed clinical trials have focused on specific targets to redirect the immune network toward eradicating a variety of tumors and ameliorating the selfdestructive process. In a previous review,...

  • Quality of Life of People Living with HIV/AIDS under the New Epidemic Characteristics in China and the Associated Factors Sun, Wei; Wu, Ming; Qu, Peng; Lu, Chunming; Wang, Lie // PLoS ONE;May2013, Vol. 8 Issue 5, p1 

    Background: Improvement of quality of life has been one of goals in health care for people living with HIV/AIDS (PLWHA). In China, the epidemic characteristics have changed and transmission is now most commonly sexual contact. However, the assessment of quality of life of PLWHA under new...

  • Candidate Antibody-Based Therapeutics Against HIV-1. Rui Gong; Weizao Chen; Dimitrov, Dimiter S. // BioDrugs;2012, Vol. 26 Issue 3, p143 

    Antibody-based therapeutics have been successfully used for the treatment of various diseases and as research tools. Several well characterized, broadly neutralizing monoclonal antibodies (bnmAbs) targeting HIV-1 envelope glycoproteins or related host cell surface proteins show sterilizing...

  • Drug news and trial developments.  // AIDS Patient Care & STDs;Mar1998, Vol. 12 Issue 3, p231 

    Presents information on drugs and trial developments in the treatment of human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS). AIDS vaccine study by VaxGen Incorporated; Study of HIV-positive patients receiving thalidomide treatment; Approval of rituximab for...

  • PHS proposes `parallel track' for new AIDS drugs.  // Public Health Reports;Sep/Oct90, Vol. 105 Issue 5, p541 

    Reports on the US Public Health Service's (PHS) proposal for speeding the availability of investigational new drugs for AIDS and HIV-related diseases by means of a parallel track mechanism. Selection of patients with life-threatening illnesses including AIDS; Views on the safeguards to parallel...


Read the Article

Other Topics